XVIPF

Xvivo Perfusion AB (publ)

Healthcare · $687M market cap

Verdict

We can't put a fair value on XVIPF right now.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth32.4% a year✓
Equity per share growth22.2% a year✓
Sales growth22.5% a year✓
Free cash flow growth—?
Return on invested capital2.1%✗

Follow XVIPF

Track it on your watchlist and see the full analysis. Free.

Create a free account

Questions about XVIPF

How can I check XVIPF's value myself?

Use the free Sticker Price calculator, already filled with XVIPF's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →

Similar stocks · Medical - Devices

About Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ) is a medical technology company dedicated to advancing transplantation medicine. The firm specializes in pioneering solutions for the preservation and perfusion of organs, tissues, and cells, essential for successful transplant procedures. With a significant international presence, Xvivo Perfusion operates across diverse markets, including Sweden, the United States, wider North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Among its key product offerings is the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass apparatus designed for normothermic ex vivo lung perfusion (EVLP). Complementing this, the company provides the XPS Disposable Lung Kit, comprising sterile, pre-packaged components required for EVLP, and STEEN Solution, a specialized buffered extracellular fluid used for perfusing isolated donor lungs during the EVLP process. Xvivo also offers Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte solution crucial for preservation. Other significant products include the XVIVO Silicone Tubing Set for rapid flushing of donor lungs post-procurement; the XVIVO LS and XVIVO Disposable Lung Set, devices engineered for EVLP; and the XVIVO Organ Chamber, a single-use sterile container designed for the temporary storage of isolated lungs prior to their transplantation into a recipient. Additionally, the XVIVO Lung Cannula Set, a sterile, single-use disposable product, is part of their portfolio. Established in 1998, Xvivo Perfusion AB (publ) maintains its headquarters in Gothenburg, Sweden.

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. How the Payback Price works